CPRX Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into CPRX


Also see:
CPRX stock yearly return 2014
CPRX stock yearly return 2015
CPRX stock yearly return 2016
CPRX stock yearly return 2017
CPRX stock yearly return 2018
CPRX stock yearly return 2019
CPRX stock yearly return 2020
CPRX stock yearly return 2021
CPRX stock yearly return 2022
CPRX stock yearly return 2023
CPRX YTD return
Compare CPRX average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 06/25/2014
End date: 06/24/2024
Start price/share: $2.46
End price/share: $15.39
Dividends collected/share: $0.00
Total return: 525.61%
CPRX Average Annual Return: 20.11%
Starting investment: $10,000.00
Ending investment: $62,550.06
Years: 10.01


CPRX average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s main US commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg approved for the treatment of Lambert-Eaton myasthenic syndrome for adults and for children ages six and up. Co. has the US rights to FYCOMPA®(perampanel) CIII, a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The CPRX average annual return 10 years is shown above.

The Average Annual Return on the CPRX average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CPRX average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CPRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CPRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Catalyst Pharmaceuticals (CPRX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CRBP Average Annual Return
CRBU Average Annual Return
CRDF Average Annual Return
CRGX Average Annual Return
CRH Average Annual Return
CRIS Average Annual Return
CRL Average Annual Return
CRMD Average Annual Return
CRNX Average Annual Return
CRVL Average Annual Return
More Healthcare companies »

★★★★★ Based on a ranking of our entire coverage universe by highest ten year average annual return, Catalyst Pharmaceuticals (CPRX) ranks in the top 25% of all stocks whose returns we have reviewed.
What has the average annual return been for CPRX over the past ten years?
✔️Accepted answer: The ten year CPRX average annual return has been 20.11%.

What start date was used in your CPRX average annual return calculation?
✔️Accepted answer: The start date was 06/25/2014.

What end date was used in your CPRX average annual return calculation?
✔️Accepted answer: The end date was 06/24/2024.

If I had invested $10,000 into CPRX ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 06/24/2024, you would have $62,550.06.

What does that work out to on a total return basis?
✔️Accepted answer: The CPRX ten year total return ending 06/24/2024 works out to 525.61%.


Also see:
CPRX stock yearly return 2014
CPRX stock yearly return 2015
CPRX stock yearly return 2016
CPRX stock yearly return 2017
CPRX stock yearly return 2018
CPRX stock yearly return 2019
CPRX stock yearly return 2020
CPRX stock yearly return 2021
CPRX stock yearly return 2022
CPRX stock yearly return 2023
CPRX YTD return
 

CPRX Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.